Funding Received
$44.8 Million in 4 Rounds from 2 Investors
Most Recent Funding
$17 Million Series D on March 25, 2014
Headquarters:
Cambridge, MA
Description:
NeuroPhage develops disease-modifying therapies for Alzheimer’s, Parkinson’s, Huntington’s, ALS, MS and other neurodegenerative diseases.
Categories:
Biotechnology
Website:
http://www.neurophage.com

Company Details

Update

NeuroPhage Pharmaceuticals, Inc., a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It offers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Current Team (1)

Update

Funding Rounds (4) - $17M

Update

Investors (2)

Update

Offices/Locations (1)

Update
  • Office

    222 Third Street

    Suite 3120

    Cambridge, MA 02142

    USA

Images (1)

Update
  • Fd5c49311c3f41ccbc3412e2f38cb347